Jonathan Mazelsky on leadership transition
From IDXX Stock | IDEXX Laboratories Inc Q1 2026 Earnings Call · · AlphaStreet
“This will be my final earnings call as CEO before I transition to the executive chair role following our annual meeting next week. As I reflect on my experience as CEO and the state of the company today, I remain incredibly optimistic about the future of Idex and the multi-decade opportunity ahead for the company. The fundamental drivers of this industry have never been stronger.”
On , Jonathan Mazelsky, President, Chief Executive Officer & Director at IDEXX Laboratories, Inc, spoke about leadership transition during IDXX Stock | IDEXX Laboratories Inc Q1 2026 Earnings Call on AlphaStreet.
About Jonathan Mazelsky
Jonathan Mazelsky, president and CEO of IDEXX Laboratories, participated in the company’s quarterly earnings calls from the first quarter of 2025 through the first quarter of 2026. During these calls, he discussed the company’s financial performance and outlook, including raising full-year revenue and EPS guidance in each quarter. In the first quarter of 2026, Mazelsky noted that this would be his final earnings call as CEO before transitioning to executive chair, and he stated that he remains “incredibly optimistic about the future of Idex.” He highlighted the launch of the IDEX Cancer DX panel, which he described as a “major evolution” in diagnostics, and noted that over 2,500 practices had ordered the test by the second quarter of 2025. Mazelsky also discussed the InView DX platform, including its ear cytology and blood morphology capabilities, and expressed excitement about the planned addition of fine-needle aspiration (FNA) testing for lumps and bumps. Mazelsky addressed industry trends, including a decline in clinical visits, which he attributed to macroeconomic pressures and consumer trade-offs, particularly in wellness visits. He stated that the company had seen “green shoots” in non-wellness visits and that diagnostic frequency and utilization continued to expand. Regarding tariffs, Mazelsky said the company was “relatively well positioned” with 65% of consolidated revenues in the U.S. and less than 1% from China, but acknowledged the company was “not immune” to a “highly dynamic tariff environment.” He also noted that the estimated pet population remained elevated compared to 2019, which he said supported “strong tailwinds” to the business.